Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IGC Pharma Inc IGC

Healthcare Cannabis
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aß plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aß plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aß plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.


NYSEAM:IGC - Post by User

IGC Pharma Inc
<< Previous
 Bullboard Posts
User Avatar Image
(230)
•••
Post by whytestockson Sep 18, 2024 6:17pm
70 Views
Post# 36229985

InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Re

InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Re
News; $IGC InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1's Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer'sIGC Pharma (NYSE American: IGC) , an AI-powered, clinical-stage biotechnology company, today announced data that supports the therapeutic potential of IGC-AD1 as a disease modifying treatment for Alzheimer&#x2019;s. According to the announcement, findings from studies have shown that IGC-AD1 has ...IGC - InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1's Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer's

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities